Literature DB >> 569482

Tight binding inhibitors--VI. Interactions of deoxycoformycin and adenosine deaminase in intact human erythrocytes and sarcoma 180 cells.

T Rogler-Brown, R P Agarwal, R E Parks.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 569482     DOI: 10.1016/0006-2952(78)90133-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

1.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.

Authors:  M K Hostetter; G M Johnson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 2.  Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.

Authors:  R I Glazer
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Deoxycoformycin toxicity in mice after long-term treatment.

Authors:  R P Agarwal
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Animal model for immune dysfunction associated with adenosine deaminase deficiency.

Authors:  A Tedde; M E Balis; S Ikehara; R Pahwa; R A Good; P P Trotta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

6.  Identification of a New Uncompetitive Inhibitor of Adenosine Deaminase from Endophyte Aspergillus niger sp.

Authors:  Xin-Guo Zhang; Jin-Wen Liu; Peng Tang; Zi-Yu Liu; Guang-Jun Guo; Qiao-Yun Sun; Jian-Jun Yin
Journal:  Curr Microbiol       Date:  2017-12-14       Impact factor: 2.188

Review 7.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.